Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 6, 2017, Pages 906-908

  Storgaard, Heidi ^a   Cold, Frederik ^a   Gluud, Lise L ^a,b   Vilsbøll, Tina ^a,b   Knop, Filip K ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Capital Region   (Denmark)

Author keywords

antidiabetic drug; GLP 1 analogue; incretin therapy; liraglutide; meta analysis; type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIXISENATIDE; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; PEPTIDE;

ACUTE PANCREATITIS; ADVERSE DRUG REACTION; ARTICLE; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ACUTE DISEASE; AGONISTS; CHEMICALLY INDUCED; ODDS RATIO; PANCREATITIS; RISK FACTOR;

ACUTE DISEASE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; ODDS RATIO; PANCREATITIS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 85019863234     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12885     Document Type: Article

References (15)

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
3. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;14:150-156.
4. Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Intern Med. 2013;173:534-539.
5. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014;370:794-797.
6. Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015;48:461-471.
7. Azoulay L, Filion KB, Platt RW, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med. 2016;176:1464-1473.
8. Wang T, Wang F, Gou Z, et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab. 2015;17:32-41.
9. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.
10. Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40(2):284-286.
11. Abbas AS, Dehbi H-M, Ray KK. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes Metab. 2016;18:295-299.
12. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257.
13. Center for Drug Evaluation and Research. FDA Drug Safety Newsletter – Postmarketing Reviews. Volume 1, Number 2, Winter 2008. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm119034.htm#exenatide. Accessed November 14, 2016.
14. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443-1451.
15. Sonne DP, Vilsbøll T, Knop FK. Pancreatic amylase and lipase plasma concentrations are unaffected by increments in endogenous GLP-1 levels following liquid meal tests. Diabetes Care. 2015;38:e71-72.